Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Royal Bank Of Canada

Royal Bank Of Canada began coverage on shares of Pharvaris (NASDAQ:PHVS) in a report issued on Monday morning, Marketbeat reports. The firm issued an outperform rating and a $52.00 price objective on the stock.

A number of other equities research analysts have also recently issued reports on the company. Wedbush raised their target price on Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Wednesday, November 19th. Bank of America lifted their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Thursday, December 4th. Oppenheimer boosted their target price on shares of Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Finally, Morgan Stanley upped their target price on shares of Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, December 4th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Pharvaris has an average rating of “Moderate Buy” and an average price target of $41.70.

Pharvaris Stock Performance

Shares of PHVS opened at $26.51 on Monday. The stock has a fifty day moving average price of $26.75 and a 200 day moving average price of $24.92. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.80.

Institutional Investors Weigh In On Pharvaris

Several institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. bought a new position in Pharvaris in the 4th quarter valued at about $35,000. JPMorgan Chase & Co. lifted its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pharvaris in the 3rd quarter worth approximately $75,000. Barclays PLC bought a new position in shares of Pharvaris in the fourth quarter valued at approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Pharvaris in the fourth quarter valued at approximately $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.